SG11201604371PA - Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease - Google Patents
Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory diseaseInfo
- Publication number
- SG11201604371PA SG11201604371PA SG11201604371PA SG11201604371PA SG11201604371PA SG 11201604371P A SG11201604371P A SG 11201604371PA SG 11201604371P A SG11201604371P A SG 11201604371PA SG 11201604371P A SG11201604371P A SG 11201604371PA SG 11201604371P A SG11201604371P A SG 11201604371PA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical composition
- inflammatory disease
- metabolic syndrome
- phenol derivative
- treating metabolic
- Prior art date
Links
- 208000001145 Metabolic Syndrome Diseases 0.000 title 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000002989 phenols Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130162909 | 2013-12-24 | ||
| KR1020140181951A KR102344479B1 (en) | 2013-12-24 | 2014-12-17 | Pyranochromenylphenol derivatives and a pharmaceutical composition for treating metabolic syndrome or inflammatory disease |
| PCT/KR2014/012688 WO2015099392A1 (en) | 2013-12-24 | 2014-12-23 | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201604371PA true SG11201604371PA (en) | 2016-07-28 |
Family
ID=53788040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201604371PA SG11201604371PA (en) | 2013-12-24 | 2014-12-23 | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9783551B2 (en) |
| EP (1) | EP3098224B1 (en) |
| JP (2) | JP6620096B2 (en) |
| KR (1) | KR102344479B1 (en) |
| CN (1) | CN105849111B (en) |
| AU (1) | AU2014370697B2 (en) |
| BR (1) | BR112016011281B1 (en) |
| CA (1) | CA2929001C (en) |
| CY (1) | CY1121554T1 (en) |
| DK (1) | DK3098224T3 (en) |
| ES (1) | ES2718878T3 (en) |
| HR (1) | HRP20190573T1 (en) |
| HU (1) | HUE043902T2 (en) |
| IL (1) | IL245908B (en) |
| MX (1) | MX374944B (en) |
| NZ (1) | NZ720328A (en) |
| PL (1) | PL3098224T3 (en) |
| PT (1) | PT3098224T (en) |
| SG (1) | SG11201604371PA (en) |
| TW (1) | TWI585093B (en) |
| WO (1) | WO2015099392A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102344479B1 (en) * | 2013-12-24 | 2021-12-29 | 주식회사 글라세움 | Pyranochromenylphenol derivatives and a pharmaceutical composition for treating metabolic syndrome or inflammatory disease |
| ES2964146T3 (en) * | 2016-06-29 | 2024-04-04 | Glaceum Inc | Optically active pyranochromenylphenol derivative and pharmaceutical composition comprising it |
| PT3524609T (en) * | 2016-10-04 | 2021-07-15 | Glaceum Inc | 3-phenyl-2,3,4,8,9,10-hexahydropyrano[2,3-f]chromene derivative and method for synthesizing optical isomer thereof |
| TWI804600B (en) | 2018-04-03 | 2023-06-11 | 南韓商格雷森伍股份有限公司 | METHOD FOR SYNTHESIZING 3-PHENYL-2,8-DIHYDROPYRANO[2,3-ƒ]CHROMENE DERIVATIVES |
| WO2019194583A1 (en) * | 2018-04-03 | 2019-10-10 | 주식회사 글라세움 | 3-phenyl-2,8-dihydropyrano[2,3-f]chromene derivative and pharmaceutical composition comprising same |
| KR20200105198A (en) | 2019-02-28 | 2020-09-07 | 주식회사 글라세움 | Pharmaceutical composition for the prevention or treatment of neurological diseases |
| KR102692932B1 (en) | 2019-07-30 | 2024-08-07 | 주식회사 글라세움 | Synthesizing Method Of 2-((6-(hydroxymethyl)chromene-5-yl)oxy)-1-phenylethanone Derivative |
| EP4353226A4 (en) | 2021-06-08 | 2024-10-16 | Glaceum, Inc. | Pharmaceutical composition for preventing or treating degenerative eye diseases |
| CN113616548B (en) * | 2021-09-02 | 2023-04-28 | 河南科技大学 | Water-soluble glabridin inclusion compound and preparation method thereof |
| US20250250279A1 (en) * | 2022-04-12 | 2025-08-07 | Glaceum Inc. | METHOD FOR SYNTHESIZING 3-PHENYL-2,3,4,8,9,10-HEXAHYDROPYRANO[2,3-f]CHROMENE DERIVATIVES |
| CN114903879B (en) * | 2022-06-23 | 2023-10-31 | 东北大学 | Use of 3-hydrocarbylphenol derivatives in the preparation of products for preventing or treating hyperlipidemia and related metabolic diseases |
| KR20240113389A (en) | 2023-01-12 | 2024-07-22 | 주식회사 글라세움 | Pharmaceutical composition for the prevention or treatment of degenerative arthritis |
| KR20250081177A (en) | 2023-11-29 | 2025-06-05 | 한국화학연구원 | Composition for preventing, improving or treating obesity in companion animals containing HSG4112 R-form as an active ingredient |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL160964A0 (en) | 2001-10-11 | 2004-08-31 | Kaneka Corp | Peroxisome proliferator activated receptor ligand and process for producing the same |
| KR100565423B1 (en) * | 2003-10-20 | 2006-03-30 | 빅 바이오 주식회사 | Method for preparing isoflavone derivatives or isoflavone derivatives |
| JP2006008604A (en) | 2004-06-25 | 2006-01-12 | Kuraray Co Ltd | Method for producing isoflavan derivative |
| KR20070052211A (en) * | 2005-11-16 | 2007-05-21 | 주식회사 엠디바이오알파 | Composition for preventing and treating disease syndrome containing glabridine as an active ingredient |
| KR102344479B1 (en) * | 2013-12-24 | 2021-12-29 | 주식회사 글라세움 | Pyranochromenylphenol derivatives and a pharmaceutical composition for treating metabolic syndrome or inflammatory disease |
-
2014
- 2014-12-17 KR KR1020140181951A patent/KR102344479B1/en active Active
- 2014-12-23 ES ES14873860T patent/ES2718878T3/en active Active
- 2014-12-23 AU AU2014370697A patent/AU2014370697B2/en active Active
- 2014-12-23 PT PT14873860T patent/PT3098224T/en unknown
- 2014-12-23 PL PL14873860T patent/PL3098224T3/en unknown
- 2014-12-23 CN CN201480070935.5A patent/CN105849111B/en active Active
- 2014-12-23 JP JP2016540481A patent/JP6620096B2/en active Active
- 2014-12-23 SG SG11201604371PA patent/SG11201604371PA/en unknown
- 2014-12-23 US US15/037,230 patent/US9783551B2/en active Active
- 2014-12-23 BR BR112016011281-4A patent/BR112016011281B1/en active IP Right Grant
- 2014-12-23 HR HRP20190573TT patent/HRP20190573T1/en unknown
- 2014-12-23 MX MX2016008429A patent/MX374944B/en active IP Right Grant
- 2014-12-23 WO PCT/KR2014/012688 patent/WO2015099392A1/en not_active Ceased
- 2014-12-23 CA CA2929001A patent/CA2929001C/en active Active
- 2014-12-23 EP EP14873860.2A patent/EP3098224B1/en active Active
- 2014-12-23 NZ NZ720328A patent/NZ720328A/en unknown
- 2014-12-23 DK DK14873860.2T patent/DK3098224T3/en active
- 2014-12-23 HU HUE14873860 patent/HUE043902T2/en unknown
- 2014-12-24 TW TW103145316A patent/TWI585093B/en active
-
2016
- 2016-05-29 IL IL245908A patent/IL245908B/en active IP Right Grant
-
2018
- 2018-03-23 JP JP2018056783A patent/JP2018135343A/en active Pending
-
2019
- 2019-04-16 CY CY20191100423T patent/CY1121554T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102344479B1 (en) | 2021-12-29 |
| CA2929001C (en) | 2018-02-20 |
| BR112016011281A2 (en) | 2017-08-08 |
| IL245908B (en) | 2020-08-31 |
| JP6620096B2 (en) | 2019-12-11 |
| DK3098224T3 (en) | 2019-05-13 |
| US20160272650A1 (en) | 2016-09-22 |
| MX2016008429A (en) | 2017-02-23 |
| JP2018135343A (en) | 2018-08-30 |
| PT3098224T (en) | 2019-04-26 |
| HUE043902T2 (en) | 2019-10-28 |
| AU2014370697A1 (en) | 2016-06-16 |
| MX374944B (en) | 2025-03-06 |
| PL3098224T3 (en) | 2019-07-31 |
| CN105849111A (en) | 2016-08-10 |
| WO2015099392A1 (en) | 2015-07-02 |
| EP3098224A1 (en) | 2016-11-30 |
| TW201607949A (en) | 2016-03-01 |
| BR112016011281B1 (en) | 2021-11-16 |
| KR20150075030A (en) | 2015-07-02 |
| JP2017501163A (en) | 2017-01-12 |
| EP3098224B1 (en) | 2019-01-30 |
| CN105849111B (en) | 2018-05-04 |
| CA2929001A1 (en) | 2015-07-02 |
| TWI585093B (en) | 2017-06-01 |
| CY1121554T1 (en) | 2020-05-29 |
| US9783551B2 (en) | 2017-10-10 |
| HRP20190573T1 (en) | 2019-05-17 |
| AU2014370697B2 (en) | 2017-01-19 |
| NZ720328A (en) | 2018-02-23 |
| IL245908A0 (en) | 2016-08-02 |
| ES2718878T3 (en) | 2019-07-05 |
| EP3098224A4 (en) | 2017-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL245908A0 (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
| PL2986304T3 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| BR112015001098A2 (en) | compound, pharmaceutical composition and method for treating a disease condition. | |
| IL243042A0 (en) | Aminotriazine derivative and pharmaceutical composition comprising the same | |
| SMT201900684T1 (en) | Combined pharmaceutical composition | |
| BR112015002738A2 (en) | compound and pharmaceutical composition | |
| PT2640205T (en) | ELECTRIC HEATED SMOKING SYSTEM UNDERSTANDING, AT LEAST, TWO UNITS | |
| SG11201509308TA (en) | Low dose pharmaceutical composition | |
| ZA201509307B (en) | Pharmaceutical composition, preparation and uses thereof | |
| LT3735962T (en) | PHARMACEUTICAL COMPOSITION COMPRISING PHOSPHATE BINDING PARTICLES | |
| EP3012292A4 (en) | TREATMENT ADJUVANT, AND COMPOSITION | |
| EP2990419A4 (en) | Preventive or therapeutic agent for inflammatory disease | |
| EP2981554A4 (en) | Methods and compositions for treating and preventing disease associated with avb8 integrin | |
| SG11201601477VA (en) | Pharmaceutical composition | |
| GB201320932D0 (en) | Topical pharmaceutical composition | |
| BR112014032501A2 (en) | compound and pharmaceutical composition. | |
| EP3020399A4 (en) | Novel pharmaceutical composition for preventing or treating cancer | |
| HUE051902T2 (en) | Pharmaceutical composition comprising a dual reuptake inhibitor and method for the preparation thereof | |
| ZA201509091B (en) | Antivirally effective pharmaceutical composition | |
| HUP1300496A2 (en) | Stable pharmaceutical composition | |
| IL244365A0 (en) | Pharmaceutical composition | |
| SG11201600119PA (en) | Compound and methods for treating long qt syndrome | |
| EP2992890A4 (en) | Pharmaceutical composition | |
| IL284405A (en) | Pharmaceutical composition, preparation and uses thereof | |
| EP2815756A4 (en) | COMPOSITION FOR PREVENTING, ENHANCING OR TREATING METABOLIC SYNDROME |